Value Sense
POAI
Predictive Oncology Inc. (POAI)
Last Price$1.3(9.4%)
Market Cap$8,155.2K
LTM P/E
(0.6x)
EPS growth
(80.7%)
PEGY
0.0x
Peter Lynch Fair Value
$174.1
Undervalued (Peter Lynch formula)
13,717.8%
Stock quality
4/10
Good
POAI
is 297.3% undervalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

POAI Peter Lynch Fair Value

Peter Lynch Fair Value Assumptions

as of Mar 09, 2025
LTM P/E
(0.6x)
EPS growth
(80.7%)
Dividend Yield
0.0%
PEGY
0.0x
Last share price
$1.3
Peter Lynch Fair Value
$174.1
13717.8% undervalued

Peter Lynch Fair Value Calculation

PEGY
0.0x
=
LTM P/E
(0.6x)
/
(
EPS growth
(80.67%)
+
Dividend yield
0.01%
)
Peter Lynch
Fair Value
$174.1
=
Last share price
$1.3
/
PEGY
0.0x

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

POAI EPS growth & Dividend Yield

Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
EPS growth
Dividend Yield

POAI vs Peer Set: Peter Lynch Fair Value Comparison

General

PETER LYNCH FAIR VALUE

Financial metrics

Company name

Undervaluation / Overvaluation

Revenue growth

EBITDA margin

Net Income margin

Predictive Oncology Inc. logo
Predictive Oncology Inc.POAI
13,717.8%
18.2%
(64.9%)
(785.6%)
Median Peer Set
3.4%
23.0%
10.4%
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
71.7%
4.2%
18.3%
8.4%
ResMed Inc. logo
ResMed Inc.RMD
(16.7%)
10.9%
13.4%
21.8%
Intuitive Surgical, Inc. logo
Intuitive Surgical, Inc.ISRG
(78.8%)
17.2%
27.7%
27.8%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
6.1%
8.4%
32.2%
10.1%
West Pharmaceutical Services, Inc. logo
West Pharmaceutical Services, Inc.WST
(58.3%)
(1.9%)
(15.5%)
17.0%
Alcon Inc. logo
Alcon Inc.ALC
(37.2%)
8.5%
182.9%
10.3%
Hologic, Inc. logo
Hologic, Inc.HOLX
(7.9%)
(0.0%)
81.1%
19.6%
AptarGroup, Inc. logo
AptarGroup, Inc.ATR
(62.9%)
2.7%
30.2%
10.5%
Masimo Corporation logo
Masimo CorporationMASI
(319.6%)
0.6%
(42.5%)
4.0%
Baxter International Inc. logo
Baxter International Inc.BAX
N/A
(69.5%)
(100.0%)
(6.9%)

Explore more intrinsic value tools hub for POAI

Margin of safety
Ben Graham Fair Value
Earnings growth model
Discount rate
Peter Lynch charts
Reverse DCF
Earnings Power Value
Intrinsic Value
DCF value calculator
Relative Value

FAQ

What is Predictive Oncology Inc. fair value by Peter Lynch formula?

As of Mar 03, 2025, Predictive Oncology Inc.'s fair value using the Peter Lynch formula is $174.1 per share. The current price of $1.3 suggests Predictive Oncology Inc. may be undervalued by this metric.

What is Predictive Oncology Inc. Price to Earnings (P/E) ratio?

As of Mar 03, 2025, Predictive Oncology Inc.'s P/E ratio is (0.6x). This is calculated by dividing the current share price of $1.3 by the Earnings per Share (EPS) for the trailing twelve months, which is ($3.1). The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.

What is Predictive Oncology Inc. earnings per share (EPS)?

Predictive Oncology Inc. earnings per share (EPS) for the twelve months ending Mar 03, 2025, was ($3.1), a (80.7%) growth year-over-year.